Payers Should Brace For Next Hepatitis C Drug “Onslaught” – Express Scripts
This article was originally published in The Pink Sheet Daily
Express Scripts anticipates that the launch of new treatments in 2014 will replicate some of the dynamics in the hepatitis C market in 2011.
You may also be interested in...
The early February date for publishing the list of products eligible for price negotiations could dictate approval strategies for drugs with potential for big sales in Medicare going forward.
Increased application of utilization management controls expected as plans face higher costs under the redesign. However, the formulary advantages available to drugs in the protected classes may lead developers to sharpen their focus on those categories.
FDA-approved language recommending ongoing patient monitoring through a registry is unusual but not unprecedented to address potential safety concerns.